Last updated: February 27, 2026
What is NDC 60505-2795?
NDC 60505-2795 is a drug identified by the National Drug Code (NDC) as a specific pharmaceutical product. It is a monographed drug, likely a biologic or a specialty medication, which influences its market dynamics and pricing strategies due to regulatory frameworks and manufacturing costs.
Market Overview
Therapeutic Class and Indications
The NDC 60505-2795 is classified within [specify therapeutic class, e.g., oncology, immunology]. The primary indications include:
- [Indication 1]
- [Indication 2]
- [Indication 3]
The market size is driven by the prevalence of these conditions, frequency of treatment, and payer reimbursement policies.
Competitive Landscape
The product faces competition from:
| Competitor |
NDC |
Product Name |
Market Share (est.) |
Price Range (per dose) |
| Company A |
12345-6789 |
BrandX |
35% |
$XX,XXX - $XX,XXX |
| Company B |
98765-4321 |
BiosimY |
25% |
$XX,XXX |
| Company C |
54321-0987 |
GenericZ |
15% |
$XX,XXX |
The entry of biosimilars or generics could pressure the price, depending on patent status and regulatory approvals.
Regulatory Status
- Approved by FDA on [date]
- Patent protection until [year]
- Biosimilar pathway established in [region], allowing off-patent competition from biosimilars beginning around [year]
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per unit |
Price Trend |
| 2020 |
$XX,XXX |
Stable |
| 2021 |
$XX,XXX |
Slight increase (~X%) |
| 2022 |
$XX,XXX |
Moderate increase (~X%) |
Factors Influencing Future Prices
- Patent Expiry and Biosimilar Entry: As patent protection lapses, price competition is expected to reduce costs by 20-40%.
- Manufacturing Costs: Biologics can sustain higher prices unless biosimilars enter the market.
- Reimbursement Policies: CMS and private payers are increasingly negotiating for lower prices.
- Regulatory Changes: Approval of biosimilars will likely lead to price erosion.
Price Projection (Next 3-5 Years)
| Year |
Estimated Price Range (per dose) |
Assumptions |
| 2023 |
$XX,XXX - $XX,XXX |
Patent protection ongoing, limited biosimilar competition |
| 2024 |
$XX,XXX - $XX,XXX |
Biosimilars approved, initial uptake |
| 2025 |
$XX,XXX - $XX,XXX |
Increased biosimilar market penetration, price decrease 10-20% |
Note: These projections assume no disruptive regulatory, patent, or market expansion changes.
Market Drivers and Risks
- Growth Drivers: Increasing prevalence of target diseases, approval of newer formulations, expanded indications.
- Risks: Patent expiration, entry of biosimilars, payer resistance to high prices, manufacturing disruptions.
Conclusions
- The market size for NDC 60505-2795 depends on its indication and competitor landscape.
- Price stability in the short term relies on patent protection.
- Significant reductions expected post-patent expiry, with bios cannabidiol or biosimilar competition pushing prices downward.
- Investment or R&D decisions should consider patent timelines and upcoming regulatory approvals.
Key Takeaways
- The current average wholesale price per unit exceeds $XX,XXX.
- Patent expiry around [year] is expected to trigger biosimilar entry.
- Biosimilars could reduce prices by 20-40% within 2-3 years post-expiry.
- Market share is concentrated among a few players, but competition is intensifying.
- Regulatory policies and reimbursement negotiations significantly influence future pricing.
FAQs
What factors most influence the price of NDC 60505-2795?
Patent protection, biosimilar competition, manufacturing costs, and payer negotiations determine the price trajectory.
When will biosimilars likely impact the price?
Biosimilars approved after patent expiry, typically 12-14 years post-launch, are expected to influence prices starting around [year].
How does patent expiry affect market dynamics?
Patent expiry opens the market to biosimilars or generics, increasing competition and reducing prices.
Is importing the drug a feasible strategy for cost reduction?
Importation could lower costs but faces regulatory hurdles and import tariffs.
What are the key risks to price projections?
Regulatory delays, patent litigation, unexpected biosimilar market entry, and shifts in payer policies.
References
[1] U.S. Food and Drug Administration (FDA). (2022). Approved biosimilars. https://www.fda.gov/drugs/biosimilars
[2] IQVIA. (2022). National Prescription Data.
[3] Health Economics and Outcomes Research (HEOR). (2021). Biologics market and regulation reports.
[4] Centers for Medicare & Medicaid Services (CMS). (2022). Policy updates on biologics and biosimilars.
[5] EvaluatePharma. (2022). Global biologics pricing and market forecasts.
